Immusmol
Entity

  • Immusmol

    Created in 2012
  • BETA

    Up & running (A)
    Existing signals show a regular activity

  • Social networks

    78 1,323

  • Activities

    biotech deeptech

  • Technologies

    Synthetic Biology

  • Entity types

    Startup

  • Location

    229 Cr de l'Argonne, 33076 Bordeaux, France

    Bordeaux

    France

  • Employees

    Scale: 11-50

    Estimated: 10

  • Engaged corporates

    1
    1 0

  • Added in Motherbase

    4 years, 10 months ago
Description
  • Value proposition

    Immusmol develops small molecule antibodies for research, diagnostics and therapy.

    Combining 25 years of experience in antigen design, we offer to target low molecular weight molecules, which are not usually addressed by antibodies, such as amino acid metabolites, lipids, saccharids, toxins, pesticide residues, small molecule drugs, ...

    Compatible with existing antibody-based technologies, our small molecule antibodies can serve for:

    > VISUALIZATION: Small molecule antibodies currently represent the only applicable technology for the visualization of small molecules in cells and tissues by IF or IHC.

    > QUANTIFICATION: Combined with ELISA/EIA technologies, small molecule antibodies enable rapid and robust detection of small molecules in biological samples (an attractive alternative to mass-spec and aptamer-based technologies).

    > MODULATION: Small molecules represent a vast class of neglected drug targets. ImmuSmol is currently developing a pipeline of proprietary monoclonal antibodies interfering with endogenous small molecules involved in cancer and CNS disorders.

    Small molecule antibodies, Small molecule detection, Small molecule visualization, Small molecule quantification, Custom small molecule antibodies, Therapeutic monoclonal antibodies, Tryptophan metabolism, Kynurenine pathway, and Anti-hapten antibodies

  • Original language

    ImmuSmol développe des anticorps capables de cibler des petites molécules. Spécialisée dans le design d'antigènes, la société est en mesure de produire des anticorps dirigés contre des acides aminés, des sucres, des lipides, des toxines, des médicaments, ... ouvrant ainsi un nouveau champ de possibilités pour la recherche, le diagnostique et la thérapie.

  • ImmuSmol I Small Molecule Antibodies & ELISA Kits I Anti Hapten Antibody DevelopmentImmuSmolAntibodies & immunoassays for small molecules

    ImmuSmol develops antibodies and immunoassays (staining & ELISA kits) to help scientists detect and quantify small molecules with easy-to-use and fast analytical tools.

    • https://www.immusmol.com/
Corporate interactions BETA
Corporate TypeTweets Articles
ILL - Institut Laue Langevin
ILL - Institut Laue Langevin
Research, Research Services
ILL - Institut Laue Langevin
Research, Research Services 		Not capitalistic
Partnership
Not event

5 Feb 2020


Similar entities
Last news
Show all articles
Social network dynamics